IBIO Stock Overview A preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for iBio Historical stock prices Current Share Price US$2.42 52 Week High US$4.98 52 Week Low US$1.02 Beta -3.39 1 Month Change -8.51% 3 Month Change 32.71% 1 Year Change 71.30% 3 Year Change -99.16% 5 Year Change -98.06% Change since IPO -99.95%
Recent News & Updates
iBio, Inc. Announces Directorate Appointments Nov 26
New major risk - Financial position Nov 14
iBio, Inc., Annual General Meeting, Nov 21, 2024 Oct 11
iBio, Inc. Announces the Appointment of Kristi Sarno as Senior Vice President of Business Development Aug 13 Texas A&M University System Board of Regents acquired Manufacturing facility located in Bryan, Texas of iBio, Inc. (NYSEAM:IBIO) for $8.5 million. Jun 05
New major risk - Financial position May 15 See more updates
iBio, Inc. Announces Directorate Appointments Nov 26
New major risk - Financial position Nov 14
iBio, Inc., Annual General Meeting, Nov 21, 2024 Oct 11
iBio, Inc. Announces the Appointment of Kristi Sarno as Senior Vice President of Business Development Aug 13 Texas A&M University System Board of Regents acquired Manufacturing facility located in Bryan, Texas of iBio, Inc. (NYSEAM:IBIO) for $8.5 million. Jun 05
New major risk - Financial position May 15 iBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC Apr 02
iBio, Inc. announced that it expects to receive $15.068742 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors Mar 27
New major risk - Financial position Feb 11 iBio, Inc. has completed a Follow-on Equity Offering in the amount of $4.780385 million. Dec 09
New major risk - Financial position Nov 17
iBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx Nov 02
iBio, Inc., Annual General Meeting, Nov 27, 2023 Oct 27
New minor risk - Insider selling Jul 17
New major risk - Market cap size Jun 29 iBio, Inc. Appoints Dr. Martin Brenner as CEO
iBio, Inc. Announces the Expansion of Its AI-Powered Technology Stack with the Launch of EngageTx Jun 07
Third quarter 2023 earnings released: US$0.48 loss per share (vs US$1.42 loss in 3Q 2022) May 16
iBio Announces MUC16 as its Latest Immune-Oncology Target Program Feb 17
First half 2023 earnings released: US$1.93 loss per share (vs US$1.97 loss in 1H 2022) Feb 16 iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023
iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023 Jan 19
High number of new and inexperienced directors Dec 29 iBio, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million. Dec 07
iBio, Inc. to Showcase the RubrYc Discovery Engine During Poster Presentations At Antibody Engineering & Therapeutics Conference 2022 Dec 06
iBio, Inc. Announces Executive Changes Dec 04 iBio, Inc. Announces the Resignation of Thomas F. Isett as a Member of the Board
iBio, Inc. Appoints William D. (Chip) Clark as Chairman Nov 04
iBio, Inc., Annual General Meeting, Dec 08, 2022 Oct 27
iBio, Inc. Files a Provisional Patent with the United States Patent and Trademark Office Title 'Epidermal Growth Factor Receptor Variant III Antibodies' Oct 16
iBio, Inc. announced delayed annual 10-K filing Sep 30 iBio, Inc. to Report Q4, 2022 Results on Sep 27, 2022
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate Aug 17
Consensus forecasts updated May 19
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat May 13
iBio, Inc. to Report Q3, 2022 Results on May 12, 2022 May 06
Price target decreased to US$1.75 Apr 27
Consensus revenue estimates fall by 52% Feb 21
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 15
iBio, Inc. to Report Q2, 2022 Results on Feb 14, 2022 Feb 08
iBio, Inc. Shares an Update on Its Lead COVID-19 Vaccine Program, IBIO-202 Jan 27
iBio, Inc Announces Update for its Lead COVID-19 Vaccine Program, IBIO-202, in Light of the Emergence of the Omicron (B.1.1.529) Variant of SARS-CoV-2 Nov 30
Price target decreased to US$2.25 Nov 30
First quarter 2022 earnings released: US$0.041 loss per share (vs US$0.047 loss in 1Q 2021) Nov 17
iBio, Inc. Provides Revenue Guidance for the First Half, Second Half and Full Year of Fiscal 2022 Sep 29
Full year 2021 earnings released: US$0.12 loss per share (vs US$0.61 loss in FY 2020) Sep 28
Independent Director Seymour Flug has left the company Sep 01
High number of new directors Aug 01
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate Jul 16 iBio, Inc.(NYSEAM:IBIO) dropped from Russell Microcap Growth Index
Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.059 loss in 3Q 2020) May 19
iBio, Inc. Reports Successful Covid-19 Vaccine Toxicology Study Results and Announces Next-Gen Covid-19 Vaccine Program May 07
iBio, Inc. and Fraunhofer USA, Inc. Concludes Litigation May 05
Revenue beats expectations Feb 18
Second quarter 2021 earnings released: US$0.043 loss per share (vs US$0.69 loss in 2Q 2020) Feb 18
iBio, Inc. Appoints Robert M. Lutz as Chief Financial & Business Officer, Effective March 4, 2021 Feb 17
iBio, Inc. to Report Q2, 2021 Results on Feb 16, 2021 Feb 10
New 90-day high: US$2.17 Feb 04
iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth Jan 07
New 90-day low: US$1.08 Dec 30
iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer Dec 29
Price target lowered to US$2.00 Dec 28
iBio, Inc. Announces Resignation of Robert L. Erwin as President Dec 24
iBio, Inc. has completed a Follow-on Equity Offering in the amount of $32.493644 million. Dec 10
iBio to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins Dec 02
iBio, Inc. to Report Q1, 2021 Results on Nov 16, 2020 Nov 06
iBio, Inc. Appoints Randy J. Maddux as Chief Operating Officer, Effective December 1, 2020 Nov 04
iBio, Inc. Announces Appointment of Members to Committees Oct 18 iBio, Inc. Appoints Gary Sender to Its Board of Directors
iBio, Inc. Announces the Appointment of Linda Armstrong to Board of Directors Oct 15
iBio Regains Compliance with NYSE American Continued Listing Standards Oct 06 Shareholder Returns IBIO US Biotechs US Market 7D -0.2% -3.3% -2.2% 1Y 71.3% -1.9% 23.9%
See full shareholder returns
Return vs Market: IBIO exceeded the US Market which returned 23.9% over the past year.
Price Volatility Is IBIO's price volatile compared to industry and market? IBIO volatility IBIO Average Weekly Movement 12.1% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: IBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IBIO's weekly volatility has decreased from 30% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company Founded Employees CEO Website 2008 16 Martin Brenner ibioinc.com
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies.
Show more iBio, Inc. Fundamentals Summary How do iBio's earnings and revenue compare to its market cap? IBIO fundamental statistics Market cap US$22.10m Earnings (TTM ) -US$14.36m Revenue (TTM ) US$175.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IBIO income statement (TTM ) Revenue US$175.00k Cost of Revenue US$0 Gross Profit US$175.00k Other Expenses US$14.53m Earnings -US$14.36m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.57 Gross Margin 100.00% Net Profit Margin -8,204.57% Debt/Equity Ratio 5.3%
How did IBIO perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 01:14 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources iBio, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Kemp Dolliver Brookline Capital Markets Kristen Kluska Cantor Fitzgerald & Co. Keay Nakae Chardan Capital Markets, LLC
Show 3 more analysts 
